Nasdaq GlobeNewswire

CompactCath Expands Product Portfolio with New Discreet Straight and Coudé Intermittent Catheters

Del

Products welcome added relief for everyday self-catheterizing users

PALO ALTO, Calif., Aug. 03, 2018 (GLOBE NEWSWIRE) -- CompactCath (www.compactcath.com), a medical device company committed to improving the quality of life for people with bladder conditions, has announced the expansion of its intermittent urinary catheter product line with the addition of CompactCath® Coudé and OneCath®. The new CE and FDA approved devices will be available from various distributors, wholesalers, and directly at www.compactcath.com.

 “Since launching the CompactCath brand, we’ve received overwhelming positive feedback from both users and clinicians, citing the catheter’s non-touch insertion, discreetness, portability, and convenience as revolutionary in comparison to current catheters available in the marketplace,” said Naama Stauber Breckler, CEO of CompactCath. “We have also found that in addition to compact catheter solutions for active lifestyles, there is a rising need for affordable catheters that don't sacrifice quality for cost, especially for the uninsured, underinsured, and those with high deductibles, and that’s why we created OneCath®.”

OneCath® has been introduced as the perfect complement to the CompactCath intermittent urinary catheter line. Available in both a straight and coudé tip in pediatric and adult sizes, OneCath® is a high quality catheter at an affordable price point, designed to improve the lives of patients and help in an industry with continuously rising healthcare costs. CompactCath is committed to eliminating the use of known carcinogens in the medical market place, and its products are 100% DEHP, BPA, and Rubber Latex free.

CompactCath® Coudé combines the compact design of CompactCath®, providing a smaller, easy to use, and discreet catheterization experience unlike traditional catheters. It is the only, pocket sized 16” long catheter with a coudé tip that fits in the palm of the hand and features a 100% non-touch system, fire-polished eyelets, silicone oil lubrication, and drainage control. CompactCath® Coudé is a welcome addition to the company’s product line, increasing the reach for those who require a curved tip to successfully drain their bladder. CompactCath® Coudé was designed for easier insertion and is the first of its kind to feature the unique “Case Up, Tip Up” design, which simplifies the catheterization process by reducing the need for visual dependency.

“With traditional coudé catheters, it’s difficult to know whether the tip is pointing in the right direction, which is crucial for proper insertion,” said Dr. Daniel Hong, CompactCath’s Chief Medical Officer. “We’ve alleviated this problem by simplifying the design of the catheter. As long as CompactCath® Coudé is held in the vertical position, the tip will also be in the vertical, upright position, allowing for correct insertion and removal throughout the catheterization process. This creates a manageable and controllable procedure by greatly reducing discomfort and the risk of catheter associated trauma to the urethra. We have invented the first catheter which eliminates the need for a guide stripe as we commonly see on coudé catheters, simplifying the insertion process and allowing users to catheterize correctly and with confidence.”

The CompactCath line now has products to fit all lifestyles and budgets, and features the following:

  • CompactCath®, ready to use, compact pocket-sized catheter
  • OneCath®, high quality catheter at an affordable price point for the underinsured and those with high deductibles
  • 100% smooth, fire-polished eyelets
  • DEHP, BPA, and Rubber Latex Free
  • User-friendly design
  • Available in straight and coudé tips in a variety of sizes for men and women
  • Available through distributors and wholesalers nationwide
  • Reimbursed by Medicare, Medicaid, and most private insurances

Along with its product expansion, CompactCath is also focused on expanding its marketing and brand awareness campaign to reach catheter users and clinicians. The company will be supporting its products with its first ever above the line advertising direct-to-consumer campaign featuring dedicated TV spots, trade shows and magazine placements to increase the reach of consumers who can benefit from these new product additions. The expanded product line will debut at the 48th Annual Meeting of the International Continence Society in Philadelphia on August 28-31, 2018.

About CompactCath  
CompactCath is committed to improving the quality of life for those who suffer from bladder conditions and need to self-catheterize. CompactCath is composed of a multidisciplinary team of physicians, engineers, and catheter users who share a passion for healthcare, design, and comfort. Established in 2012 at Stanford University, CompactCath is driven by the goal to design medical devices that enable those with chronic conditions to lead active, thriving, independent lives.

Press Contact: Carlos Wilson (carloswilson@tandemcomms.com)
845.242.4440

Photos accompanying this announcement are available at:

http://www.globenewswire.com/NewsRoom/AttachmentNg/0cd1f2ba-05e8-498c-8265-ee8dae2a9e9e

http://www.globenewswire.com/NewsRoom/AttachmentNg/6b6929dc-53a4-4acc-b981-0145486f4854

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Feelunique–Europe’s largest online beauty retailer–expands partnership with Moovweb13.12.2018 03:28Pressemelding

Feelunique will introduce a new App-like Mobile Site powered by Moovweb SAN FRANCISCO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Feelunique, Europe’s largest online beauty retailer, announced today that it has expanded its long-standing partnership with Moovweb, by building an innovative Progressive Web App (PWA) with The Moovweb Experience Delivery Network (XDN) that powers modern mobile experiences for the world’s leading brands. The company’s new eCommerce experience will allow shoppers to browse, checkout and purchase items as fast as an app in their mobile browser without requiring a mobile app download. Powered by The Moovweb XDN, the new web experience will dramatically speed up mobile shopping–search, browsing and buying products–leveraging PWA technology. Now that page load speed is a key factor for SEO thanks to new rules that rank which mobile sites appear first on Google, best-in-class eCommerce brands are utilizing PWA technology. With PWAs, follow-up pages are pre-cached giving t

Chvaletice Manganese Project Mineral Resource Update, 2018 Metallurgical Testwork Program Update and Preliminary 2019 Plans13.12.2018 03:03Pressemelding

HIGHLIGHTS: Successful 2018 Drilling Program results in updated Mineral Resource Estimate with 98.3% of Resource classified in Measured Category. Drilling Program confirmed outstanding consistency of manganese grade and mineralogy. Successful Metallurgical Testwork Program and Pilot Plant Test runs, indicating manganese can be extracted from Chvaletice tailings using a combination of proven commercial technologies. Testwork Program confirmed the proposed hydrometallurgical process can produce Ultra-High-Purity Manganese Products meeting or exceeding customer specifications. Plan to build and commission a Demonstration Plant in 2019 to produce multi-tonne, Ultra-High-Purity Manganese Product samples for customer testing and qualification. Project timeline remains on track, with Preliminary Economic Assessment targeted for release in early 2019. Targeting production of both electrolytic manganese metal and manganese sulphate monohydrate, focusing principally on Europe's rapidly emerging

Quantenna and Telefónica Reinforce Strategic Partnership with New Portfolio of 8x8 MIMO Wi-Fi 6 Products12.12.2018 23:00Pressemelding

SAN JOSE, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ: QTNA) is further strengthening its strategic partnership with Telefónica. Through a long history of cooperation, the two companies have developed multiple generations of best-in-class products including gateways, repeaters and set-top boxes deployed in Europe and Latin America. Leveraging Quantenna’s 8x8 QSR10GU-AX, Telefónica is delivering a new portfolio of high-end fiber gateways and repeaters. The Wi-Fi 6 compliant QSR10GU-AX provides integrated dual-band, dual-concurrent 2.4GHz and 5GHz functionality in the same chipset, supporting up to a maximum speed of 10Gbps and 12 simultaneous streams. Thanks to its “Always-On DFS” feature, the QSR10GU-AX offers enhanced radar detection and spectrum analyzer capabilities with wide frequency range analysis. The QSR10GU-AX also supports advanced MU-MIMO, allowing for transmission to multiple devices at the same time, and providing higher throughput, inc

Improved Accuracy and Speed for Disease Research, Two Genomic Companies Integrate Kits and Software to Enable Deep Exploration of Epigenetic Data12.12.2018 21:16Pressemelding

OnRamp’s ROSALIND and Active Motif offer an improved ChIP-Seq data analysis experience for researchers with state-of-the-art dynamics track plots and advanced collaboration capabilities SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- OnRamp BioInformatics, a genomics company focused on scientist-friendly bioinformatics software solutions, today announced they are working with Active Motif to improve accuracies in data analysis for ChIP-Seq experiments. OnRamp’s flagship software, ROSALIND, provides a point-and-click experience to speed up and simplify the process of genomic data analysis from experiment setup to QC and interactive data visualization to interpretation. With this integration, researchers will now benefit from an optimized analysis that includes the unique characteristics of Active Motif kits and antibodies, including Unique Molecular Identifiers (UMI) and spike-in solutions. Active Motif customers will now be able to rapidly interpret their data with ROSALIND’s identificati

Markforged launches H13 tool steel for high-strength, high-temp tooling applications12.12.2018 15:00Pressemelding

New material for Metal X 3D printing system is first of many WATERTOWN, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Markforged, the Boston-area 3D printer company transforming manufacturing, today announced the launch of H13 tool steel for the Metal X, the world’s leading desktop-sized metal printer with over 150 systems shipped since March 2018. The expansion into H13 will enable customers to print parts in high-strength, high-temperature applications such as metal forming tools, dies and punches, and hardened inserts for fixtures, and even injection molds with conformal cooling channels. To learn more about H13 tool steel and place an order, please visit http://markforged.com/h13 “We designed the Metal X system to change the way things are made, and the launch of H13 is the next step down that path,” said Jon Reilly, Markforged VP of product. “For manufacturers of high-volume plastic parts this is a game changer, significantly accelerating the speed at which they can bring new products

XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease12.12.2018 14:30Pressemelding

Bermekimab Therapy Rapidly and Significantly Reduces Disease AUSTIN, Texas, Dec. 12, 2018 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) has completed and the study met all primary and secondary endpoints. Thirty eight patients in two treatment groups received a low (n=10) or high (n=28) dose of bermekimab once weekly for either a 4 or 7-week treatment regimen, respectively. Statistically significant improvement was seen for all efficacy endpoints in the high dose group; and a significant dose response for the high dose compared to low dose group was observed for key endpoints, including the Eczema Area and Severity Index (EASI), Global Individual Sign Score (GISS), Patient Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), and SCORing Atopic Dermatitis (SCORAD). While clinically and statistically significant

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom